homogentisate 1,2-dioxygenaseGenealiases: AKU · HGO
Q-omics provides the consensus-scored HGD profile across patient tissues and cancer cell-line models. HGD expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HGD is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, HGD RNA expression shows 14,711 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, THCA, and ESCA as cancer lineages where HGD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HGD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HGD survival associations across molecular data types. HGD RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HGD RNA expression–survival associations across cancer types. High HGD expression shows unfavorable associations in ACC, MESO and LGG, but favorable associations in OV, KIRC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HGD RNA expression.
This table summarizes HGD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HGD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HGD shows lower tumor expression in THCA, KICH, COAD and LUSC and higher tumor expression in LUAD and UCEC. The THCA box plot shows higher HGD RNA expression in normal versus tumor tissue (log2 FC = −5.653, t-test p < 0.001).
This table shows molecular features associated with HGD in patient tissues and cancer cell lines. In patient samples, HGD shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, HGD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BREAST.
